公开(公告)号：US20150368207A1

公开(公告)日：2015-12-24

申请号：US14803650

申请日：2015-07-20

申请人： UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. ,  ADVANCED CANCER THERAPEUTICS, LLC

发明人： Robert A. Mitchell ,  John O. Trent ,  Pooran Chand ,  Gilles Hugues Tapolsky

IPC分类号： C07D239/30 ,  C07D239/42 ,  C07D409/04 ,  C07D239/38 ,  C07D405/04 ,  C07D401/04

CPC分类号： C07D239/30 ,  C07D239/38 ,  C07D239/42 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04

摘要： Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula I: wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions that contain a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions that include administering a safe and effective amount of a Formula I compound.

摘要翻译： 本文提供了可用于抑制巨噬细胞迁移抑制因子（MIF）的化合物，其具有式I：其中A选自芳族或非芳族环，双环，多环，烯烃或炔; B是H，OH，OR，SR，NH 2，NHR或烷基; R是H或烷基，X和Y独立地是N或CH，但X和Y中的一个必须为N.还提供了含有式I化合物的药物组合物和用于治疗MIF牵连的疾病或病症的方法 包括施用安全有效量的式I化合物。

公开(公告)号：US20180009764A1

公开(公告)日：2018-01-11

申请号：US15708827

申请日：2017-09-19

申请人： UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. ,  ADVANCED CANCER THERAPEUTICS, LLC

发明人： Robert A. Mitchell ,  John O. Trent ,  Pooran Chand ,  Gilles Hugues Tapolsky

IPC分类号： C07D239/30 ,  C07D401/04 ,  C07D239/38 ,  C07D239/42 ,  C07D409/04 ,  C07D405/04

CPC分类号： C07D239/30 ,  C07D239/38 ,  C07D239/42 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04

摘要： Compounds useful for the inhibition of macrophage migration inhibitory factor (MIF) are provided herein, having the Formula I: wherein A is selected from the group consisting of aromatic or non-aromatic rings, bicyclic rings, polycyclic rings, alkenes or alkynes; B is H, OH, OR, SR, NH2, NHR, or alkyl; R is H or alkyl, and X and Y are independently N or CH, but one of X and Y must be N. Also provided are pharmaceutical compositions that contain a Formula I compound and methods for the treatment of MIF-implicated diseases or conditions that include administering a safe and effective amount of a Formula I compound.